These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 25623694)
1. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Al Hussein Al Awamlh B; Lee R; Chughtai B; Donat SM; Sandhu JS; Herr HW Urology; 2015 Feb; 85(2):381-6. PubMed ID: 25623694 [TBL] [Abstract][Full Text] [Related]
2. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. Green DA; Rink M; Cha EK; Xylinas E; Chughtai B; Scherr DS; Shariat SF; Lee RK BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598 [TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France]. Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343 [TBL] [Abstract][Full Text] [Related]
4. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? Wong KA; Zisengwe G; Athanasiou T; O'Brien T; Thomas K BJU Int; 2013 Sep; 112(5):561-7. PubMed ID: 23819486 [TBL] [Abstract][Full Text] [Related]
5. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887 [TBL] [Abstract][Full Text] [Related]
6. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681 [TBL] [Abstract][Full Text] [Related]
7. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer. Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740 [TBL] [Abstract][Full Text] [Related]
8. An analysis of the efficacy, safety, and cost-effectiveness of fulguration under local anesthesia for small-sized recurrent masses: a comparative analysis to transurethral resection of bladder tumors in a matched cohort. Park DS; Hwang JH; Gong IH; Choi DK; Kang MH; Oh JJ J Endourol; 2013 Oct; 27(10):1240-4. PubMed ID: 23964922 [TBL] [Abstract][Full Text] [Related]
9. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Lotan Y; Svatek RS; Sagalowsky AI Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567 [TBL] [Abstract][Full Text] [Related]
13. Office-based Bladder Tumor Fulguration and Surveillance: Indications and Techniques. O'Neil BB; Lowrance WT Urol Clin North Am; 2013 May; 40(2):175-82. PubMed ID: 23540776 [TBL] [Abstract][Full Text] [Related]
14. Commentary on "Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?" Wong KA, Zisengwe G, Athanasiou T, O'Brien T, Thomas K, The Urology Centre, Guys and St. Thomas' NHS Foundation Trust.: BJU Int 2013; 112(5):561-7. doi:10.1111/bju.12216. [Epub 2013 Jul 2]. See WA Urol Oncol; 2014 Nov; 32(8):1350-1. PubMed ID: 25488386 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. Donat SM; North A; Dalbagni G; Herr HW J Urol; 2004 Feb; 171(2 Pt 1):636-9. PubMed ID: 14713776 [TBL] [Abstract][Full Text] [Related]
16. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?]. Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Garfield SS; Gavaghan MB; Armstrong SO; Jones JS Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507 [TBL] [Abstract][Full Text] [Related]
18. Active surveillance for low-risk bladder cancer. Tiu A; Jenkins LC; Soloway MS Urol Oncol; 2014 Jan; 32(1):33.e7-10. PubMed ID: 23518309 [TBL] [Abstract][Full Text] [Related]
19. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden. Dansk V; Malmström PU; Bläckberg M; Malmenäs M Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197 [TBL] [Abstract][Full Text] [Related]
20. [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases]. Lazica DA; Böttcher S; Degener S; von Rundstedt FC; Brandt AS; Roth S; Störkel S; Mathers MJ Aktuelle Urol; 2013 Mar; 44(2):124-8. PubMed ID: 23580383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]